Immucell
ICCC • NASDAQ
Immucell is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO F. Olivier Te Boekhorst, with a market cap of $59.0M.
CEOF. Olivier Te Boekhorst
Next Earnings
Upcoming earnings announcement for Immucell
Date
Wednesday, May 13, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
Earnings History
Past 12 earnings reports for Immucell
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Q4 2025 | -$0.31 | — | $7.6M | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.02 | — | $5.5M | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | $0.06 | — | $6.4M | — | 10-Q |
| May 14, 2025 | Q1 2025 | $0.16 | — | $8.1M | — | 10-Q |
| Feb 25, 2025 | Q4 2024 | $0.06 | — | $7.8M | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.09 | — | $6.0M | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.20 | — | $5.5MEst: $3.3M | +67.9% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.06 | — | $7.3M | — | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$0.15 | — | $5.1M | — | — |
| Nov 13, 2023 | Q3 2023 | -$0.12 | — | $5.4M | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.18 | — | $3.5M | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.30 | — | $3.4M | — | 10-Q |